大麻改由附表一改列附表三,允许更广泛的医疗用途和研究。 Cannabis rescheduled from Schedule I to III, allowing wider medical use and research.

FundCanna在美国联邦政府决定将大麻从附表一改订为附表三管制物质之后发表了一项声明,标志着联邦政策发生了重大转变。 FundCanna issued a statement following the U.S. federal government's decision to reschedule cannabis from a Schedule I to a Schedule III controlled substance, marking a significant shift in federal policy. 该举措于2025年12月18日生效,承认大麻的公认医疗用途,并减少研究和治疗的监管障碍。 The move, effective December 18, 2025, acknowledges cannabis's accepted medical use and reduces regulatory barriers for research and treatment. 该公司欢迎这一变化,认为这是朝着扩大医疗大麻行业的准入和合法性迈出的一步。 The company welcomed the change as a step toward greater access and legitimacy in the medical cannabis industry.